[
  {
    "ts": null,
    "headline": "Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight",
    "summary": "Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia areata emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].",
    "url": "https://finnhub.io/api/news?id=bec7b4ee53109b3dea9eb0192e53d29dfe2ed8ad819cb953f983f4a23a28bb06",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771540260,
      "headline": "Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight",
      "id": 139152763,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia areata emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].",
      "url": "https://finnhub.io/api/news?id=bec7b4ee53109b3dea9eb0192e53d29dfe2ed8ad819cb953f983f4a23a28bb06"
    }
  },
  {
    "ts": null,
    "headline": "3 Stocks to Buy and Hold for 2026 and Beyond",
    "summary": "Any of these three pharmaceutical titans could move the needle in your portfolio.",
    "url": "https://finnhub.io/api/news?id=6e5fd6c47d86103ff015768f3468386cfc21d06d7454c45b9d6577f05f100297",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771522500,
      "headline": "3 Stocks to Buy and Hold for 2026 and Beyond",
      "id": 139150316,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Any of these three pharmaceutical titans could move the needle in your portfolio.",
      "url": "https://finnhub.io/api/news?id=6e5fd6c47d86103ff015768f3468386cfc21d06d7454c45b9d6577f05f100297"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Declares Quarterly Dividend",
    "summary": "The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share.",
    "url": "https://finnhub.io/api/news?id=edddbcd56ec364d9954c17a4786eef16201277fbdeea0059e27a1b70b226afe5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771511820,
      "headline": "AbbVie Declares Quarterly Dividend",
      "id": 139149015,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share.",
      "url": "https://finnhub.io/api/news?id=edddbcd56ec364d9954c17a4786eef16201277fbdeea0059e27a1b70b226afe5"
    }
  },
  {
    "ts": null,
    "headline": "Should AbbVie’s (ABBV) Post-Humira Pipeline Progress Prompt a Fresh Look From Investors?",
    "summary": "AbbVie recently reported record 2025 results and outlined a stronger 2026 outlook, while advancing key immunology assets and completing the VOLITE skin quality aesthetics trial to bolster its post-Humira growth profile. These updates, alongside reduced short interest and new Rinvoq regulatory progress, underscore how AbbVie is broadening its earnings base beyond a single flagship franchise. Now we'll examine how the completed VOLITE aesthetics trial and broader pipeline progress may reshape...",
    "url": "https://finnhub.io/api/news?id=81d5c2524f49ce48e6bb4641c357704a1a0da1ba019c7823d098b3b725f10837",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771503357,
      "headline": "Should AbbVie’s (ABBV) Post-Humira Pipeline Progress Prompt a Fresh Look From Investors?",
      "id": 139146177,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie recently reported record 2025 results and outlined a stronger 2026 outlook, while advancing key immunology assets and completing the VOLITE skin quality aesthetics trial to bolster its post-Humira growth profile. These updates, alongside reduced short interest and new Rinvoq regulatory progress, underscore how AbbVie is broadening its earnings base beyond a single flagship franchise. Now we'll examine how the completed VOLITE aesthetics trial and broader pipeline progress may reshape...",
      "url": "https://finnhub.io/api/news?id=81d5c2524f49ce48e6bb4641c357704a1a0da1ba019c7823d098b3b725f10837"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength",
    "summary": "Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength",
    "url": "https://finnhub.io/api/news?id=96e3fc6efdb528d07fa429fb29b2395f0f2ca3d29500e1fba64ce68321874c99",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771500536,
      "headline": "Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength",
      "id": 139149509,
      "image": "",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=96e3fc6efdb528d07fa429fb29b2395f0f2ca3d29500e1fba64ce68321874c99"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Increases Quarterly Dividend From $1.64 To $1.73 Per Share",
    "summary": "The cash dividend is payable May 15, 2026, to stockholders of record at the close of business on April 15, 2026.",
    "url": "https://finnhub.io/api/news?id=f4d76cec6510731623810300d1fcb2a59f70a2b59b0a8034a8d45bd6d3db1cf4",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771497657,
      "headline": "AbbVie Increases Quarterly Dividend From $1.64 To $1.73 Per Share",
      "id": 139147967,
      "image": "",
      "related": "ABBV",
      "source": "Benzinga",
      "summary": "The cash dividend is payable May 15, 2026, to stockholders of record at the close of business on April 15, 2026.",
      "url": "https://finnhub.io/api/news?id=f4d76cec6510731623810300d1fcb2a59f70a2b59b0a8034a8d45bd6d3db1cf4"
    }
  },
  {
    "ts": null,
    "headline": "Here's How Much $1000 Invested In AbbVie 10 Years Ago Would Be Worth Today",
    "summary": "",
    "url": "https://finnhub.io/api/news?id=272731af3c4743bd371b6d5630d9e6f607b4a77e65ad455142ee80175c5f9e2e",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771496127,
      "headline": "Here's How Much $1000 Invested In AbbVie 10 Years Ago Would Be Worth Today",
      "id": 139147968,
      "image": "",
      "related": "ABBV",
      "source": "Benzinga",
      "summary": " ",
      "url": "https://finnhub.io/api/news?id=272731af3c4743bd371b6d5630d9e6f607b4a77e65ad455142ee80175c5f9e2e"
    }
  },
  {
    "ts": null,
    "headline": "2 Dividend Stocks to Hold for the Next 5 Years",
    "summary": "Income investors can rest easy owning these stocks.",
    "url": "https://finnhub.io/api/news?id=a5581dcfaf0512f1c9389178fbaefc69bab42070735f7bcf0bc293bfd5104928",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771491900,
      "headline": "2 Dividend Stocks to Hold for the Next 5 Years",
      "id": 139144178,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Income investors can rest easy owning these stocks.",
      "url": "https://finnhub.io/api/news?id=a5581dcfaf0512f1c9389178fbaefc69bab42070735f7bcf0bc293bfd5104928"
    }
  },
  {
    "ts": null,
    "headline": "Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited",
    "summary": "AbbVie Inc. (NYSE:ABBV) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. AbbVie Inc. (NYSE:ABBV) tops our list for being one of the most promising stocks. TheFly reported on February 4 that Evercore ISI lowered its price target on ABBV to $228 from $232 and maintained an Outperform rating. The firm noted that although Tremfya […]",
    "url": "https://finnhub.io/api/news?id=4bdff8c526395744f3053058e5b4a744b799772e619564404e4be86732a8a3bb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771468433,
      "headline": "Evercore Notes AbbVie Inc.’s (ABBV) Tremfya Gains Market Share, But Future Earnings Growth May Be Limited",
      "id": 139141725,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. AbbVie Inc. (NYSE:ABBV) tops our list for being one of the most promising stocks. TheFly reported on February 4 that Evercore ISI lowered its price target on ABBV to $228 from $232 and maintained an Outperform rating. The firm noted that although Tremfya […]",
      "url": "https://finnhub.io/api/news?id=4bdff8c526395744f3053058e5b4a744b799772e619564404e4be86732a8a3bb"
    }
  }
]